Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Iron-deficiency Anemia Condition: Hb less than 10 g/dL or less than 6.2 mmol/L |
Dose: Injection – 500 mg Note: A single administration should not exceed 15 mg iron/kg body weight for intravenous injection or 20 mg iron/kg body weight for intravenous infusion, and should not exceed 1,000 mg of iron. The maximum recommended cumulative dose is 1,000 mg of iron per week. Haemoglobin level should be re-assessed no earlier than 4 weeks post final administration. |
|
Indication: Iron-deficiency Anemia Condition: Hb less than 10 g/dL or less than 6.2 mmol/L |
Dose: Injection – 1500 mg Note: A single administration should not exceed 15 mg iron/kg body weight for intravenous injection or 20 mg iron/kg body weight for intravenous infusion, and should not exceed 1,000 mg of iron. The maximum recommended cumulative dose is 1,000 mg of iron per week. Haemoglobin level should be re-assessed no earlier than 4 weeks post final administration. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Form – Not specified Note: Safety and efficacy not established |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Haemodialysis-dependent chronic kidney disease |
Dose: Iron – 200 mg Frequency: once daily Note: A single maximum daily dose of 200 mg iron should not be exceeded in haemodialysis-dependent chronic kidney disease patients |
|
Condition: Nondialysis dependent chronic kidney disease |
Dose: Intravenous – 750 mg Frequency: once, follow 7 days later with second 750 mg dose Note: Not to exceed cumulative dose of 1500 mg per course |
Administration
- Given as IV infusion
- Must be diluted before use
Side Effect
- Nausea (7.2%)
- Hypertension (3.8%)
- Flushing (3.6%)
- Decreased blood phosphorus (2.1%)
- Dizziness (2%)
- Vomiting (1.7%)
- Pruritus (1.5%)
- Rash (1.5%)
- Urticaria (1.5%)
- Wheezing (1.5%)
- Injection site discoloration (1.4%)
- Headache (1.2%)
- Increased alanine aminotransferase (1.1%)
- Dysgeusia (1.1%)
- Hypotension 1%)
- Constipation (0.5%)
- Serious anaphylactic/anaphylactoid reactions (0.1%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
No interactions listed
|
-
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Do not store above 30°C. Do not freeze.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.